{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T11:12:06Z","timestamp":1792062726627,"version":"4.4.0"},"reference-count":36,"publisher":"American Academy of Pediatrics (AAP)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2008,1,1]]},"abstract":"<jats:p>OBJECTIVE. With this study we assessed the efficacy and safety of an extended-release formulation of guanfacine compared with placebo for the treatment of children and adolescents with attention-deficit\/hyperactivity disorder.<\/jats:p>\n                  <jats:p>METHODS. In this multicenter, double-blind, placebo-controlled, fixed-dosage escalation study, patients aged 6 to 17 years were randomly assigned to 1 of 3 treatment groups of guanfacine extended release (2, 3, or 4 mg\/day) or placebo for 8 weeks. The primary outcome measurement was the Attention-Deficit\/Hyperactivity Disorder Rating Scale IV total score. Secondary measurements included Clinical Global Impression of Improvement, Parent's Global Assessment, Conners' Parent Rating Scale\u2013Revised: Short Form, and Conners' Teacher Rating Scale\u2013Revised: Short Form.<\/jats:p>\n                  <jats:p>RESULTS. A total of 345 patients were randomly assigned to placebo (n = 86) or guanfacine extended release 2 mg (n = 87), 3 mg (n = 86), or 4 mg (n = 86) treatment groups. Least-squares mean changes from baseline to the end point in Attention-Deficit\/Hyperactivity Disorder Rating Scale IV total scores were significant in all groups of children taking guanfacine extended release: \u221216.18 in the 2-mg group, \u221216.43 in the 3-mg group, and \u221218.87 in the 4-mg group, compared with \u22128.48 in the placebo group. All groups of children taking guanfacine extended release showed significant improvement on hyperactivity\/impulsivity and inattentiveness subscales of the Attention-Deficit\/Hyperactivity Disorder Rating Scale IV, Clinical Global Impression of Improvement, Parent's Global Assessment, Conners' Parent Rating Scale\u2013Revised: Short Form, and Conners' Teacher Rating Scale\u2013Revised: Short Form assessments compared with placebo. The most commonly reported treatment-emergent adverse events were headache, somnolence, fatigue, upper abdominal pain, and sedation. Small to modest changes in blood pressure, pulse rate, and electrocardiogram parameters were observed but were not clinically meaningful.<\/jats:p>\n                  <jats:p>CONCLUSIONS. Guanfacine extended release met the primary and secondary efficacy end points. It was well tolerated and effective compared with placebo.<\/jats:p>","DOI":"10.1542\/peds.2006-3695","type":"journal-article","created":{"date-parts":[[2007,12,31]],"date-time":"2007-12-31T12:23:13Z","timestamp":1199103793000},"page":"e73-e84","source":"Crossref","is-referenced-by-count":271,"title":["A Randomized, Double-Blind, Placebo-Controlled Study of Guanfacine Extended Release in Children and Adolescents With Attention-Deficit\/Hyperactivity Disorder"],"prefix":"10.1542","volume":"121","author":[{"given":"Joseph","family":"Biederman","sequence":"first","affiliation":[{"name":"Pediatric Psychopharmacology Department, Massachusetts General Hospital, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raun D.","family":"Melmed","sequence":"additional","affiliation":[{"name":"General Pediatrics, Melmed Center, Scottsdale, Arizona"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anil","family":"Patel","sequence":"additional","affiliation":[{"name":"Psychiatric Centers at San Diego, San Marcos, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith","family":"McBurnett","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, University of California, San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Konow","sequence":"additional","affiliation":[{"name":"Late Phase Research, Kendle International Inc, Cincinnati, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Lyne","sequence":"additional","affiliation":[{"name":"Shire Pharmaceutical Development Ltd, Basingstoke, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noreen","family":"Scherer","sequence":"additional","affiliation":[{"name":"Shire Development, Inc, Wayne, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"for the SPD503 Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"417","published-online":{"date-parts":[[2008,1,1]]},"reference":[{"key":"2021120902192030400_R1","unstructured":"Olfson M. New options in the pharmacological management of attention-deficit\/hyperactivity disorder. Am J Manag Care.\u20082004;10(suppl 4):S117\u2013S124"},{"key":"2021120902192030400_R2","doi-asserted-by":"crossref","unstructured":"Wolraich ML, Hannah JN, Pinnock TY, Baumgaertel A, Brown J. Comparison of diagnostic criteria for attention-deficit hyperactivity disorder in a county-wide sample. J Am Acad Child Adolesc Psychiatry.\u20081996;35:319\u2013324","DOI":"10.1097\/00004583-199603000-00013"},{"key":"2021120902192030400_R3","doi-asserted-by":"crossref","unstructured":"Shaffer D, Fisher P, Dulcan MK, et al. The NIMH Diagnostic Interview Schedule for Children Version 2.3 (DISC-2.3): description, acceptability, prevalence rates, and performance in the MECA Study. Methods for the Epidemiology of Child and Adolescent Mental Disorders Study. J Am Acad Child Adolesc Psychiatry.\u20081996;35:865\u2013877","DOI":"10.1097\/00004583-199607000-00012"},{"key":"2021120902192030400_R4","doi-asserted-by":"crossref","unstructured":"Bird HR, Canino G, Rubio-Stipec M, et al. Estimates of the prevalence of childhood maladjustment in a community survey in Puerto Rico: the use of combined measures. Arch Gen Psychiatry.\u20081988;45:1120\u20131126","DOI":"10.1001\/archpsyc.1988.01800360068010"},{"key":"2021120902192030400_R5","unstructured":"Crenshaw TM, Kavale K, Forness SR. Attention deficit hyperactivity disorder and the efficacy of stimulant medication: a meta analysis. In: Scruggs TE, Mataro M, eds. Advances in Learning and Behavioral Disabilities. Greenwich, CT: JAI Press; 1999:135\u2013165"},{"key":"2021120902192030400_R6","doi-asserted-by":"crossref","unstructured":"Elia J, Ambrosini PJ, Rapoport JL. Treatment of attention-deficit-hyperactivity disorder. N Engl J Med.\u20081999;340:780\u2013788","DOI":"10.1056\/NEJM199903113401007"},{"key":"2021120902192030400_R7","doi-asserted-by":"crossref","unstructured":"Gillberg C, Melander H, von Knorring AL, et al. Long-term stimulant treatment of children with attention-deficit hyperactivity disorder symptoms: a randomized, double-blind, placebo-controlled trial. Arch Gen Psychiatry.\u20081997;54:857\u2013864","DOI":"10.1001\/archpsyc.1997.01830210105014"},{"key":"2021120902192030400_R8","doi-asserted-by":"crossref","unstructured":"The MTA Cooperative Group. A 14-month randomized clinical trial of treatment strategies for attention-deficit\/hyperactivity disorder: Multimodal Treatment Study of Children With ADHD. Arch Gen Psychiatry.\u20081999;56:1073\u20131086","DOI":"10.1001\/archpsyc.56.12.1073"},{"key":"2021120902192030400_R9","doi-asserted-by":"crossref","unstructured":"Lowe TL, Cohen DJ, Detlor J, Kremenitzer MW, Shaywitz BA. Stimulant medications precipitate Tourette's syndrome. JAMA.\u20081982;247:1168\u20131169","DOI":"10.1001\/jama.247.8.1168"},{"key":"2021120902192030400_R10","doi-asserted-by":"crossref","unstructured":"Lipkin PH, Goldstein IJ, Adesman AR. Tics and dyskinesias associated with stimulant treatment in attention-deficit hyperactivity disorder. Arch Pediatr Adolesc Med.\u20081994;148:859\u2013861","DOI":"10.1001\/archpedi.1994.02170080089017"},{"key":"2021120902192030400_R11","doi-asserted-by":"crossref","unstructured":"Barkley RA, McMurray MB, Edelbrock CS, Robbins K. Side effects of methylphenidate in children with attention deficit hyperactivity disorder: a systemic, placebo-controlled evaluation. Pediatrics.\u20081990;86:184\u2013192","DOI":"10.1542\/peds.86.2.184"},{"key":"2021120902192030400_R12","doi-asserted-by":"crossref","unstructured":"Borcherding BG, Keysor CS, Rapoport JL, Elia J, Amass J. Motor\/vocal tics and compulsive behaviors on stimulant drugs: is there a common vulnerability?Psychiatry Res.\u20081990;33:83\u201394","DOI":"10.1016\/0165-1781(90)90151-T"},{"key":"2021120902192030400_R13","doi-asserted-by":"crossref","unstructured":"Garfinkel BD, Wender PH, Sloman L, O'Neill I. Tricyclic antidepressant and methylphenidate treatment of attention deficit disorder in children. J Am Acad Child Psychiatry.\u20081983;22:343\u2013348","DOI":"10.1016\/S0002-7138(09)60669-5"},{"key":"2021120902192030400_R14","unstructured":"Casat CD, Pleasants DZ, Van Wyck FJ. A double-blind trial of bupropion in children with attention deficit disorder. Psychopharmacol Bull.\u20081987;23:120\u2013122"},{"key":"2021120902192030400_R15","doi-asserted-by":"crossref","unstructured":"Riddle MA, Bernstein GA, Cook EH, Leonard HL, March JS, Swanson JM. Anxiolytics, adrenergic agents, and naltrexone. J Am Acad Child Adolesc Psychiatry.\u20081999;38:546\u2013556","DOI":"10.1097\/00004583-199905000-00016"},{"key":"2021120902192030400_R16","doi-asserted-by":"crossref","unstructured":"Hunt RD, Arnsten AF, Asbell MD. An open trial of guanfacine in the treatment of attention-deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry.\u20081995;34:50\u201354","DOI":"10.1097\/00004583-199501000-00013"},{"key":"2021120902192030400_R17","doi-asserted-by":"crossref","unstructured":"Connor DF, Barkley RA, Davis HT. A pilot study of methylphenidate, clonidine, or the combination in ADHD comorbid with aggressive oppositional defiant or conduct disorder. Clin Pediatr (Phila).\u20082000;39:15\u201325","DOI":"10.1177\/000992280003900102"},{"key":"2021120902192030400_R18","doi-asserted-by":"crossref","unstructured":"Hunt RD, Minderaa RB, Cohen DJ. Clonidine benefits children with attention deficit disorder and hyperactivity: report of a double-blind placebo-crossover therapeutic trial. J Am Acad Child Psychiatry.\u20081985;24:617\u2013629","DOI":"10.1016\/S0002-7138(09)60065-0"},{"key":"2021120902192030400_R19","doi-asserted-by":"crossref","unstructured":"Hunt RD, Capper L, O'Connell P. Clonidine in child and adolescent psychiatry. J Child Adolesc Psychopharmacol.\u20081990;1:87\u2013102","DOI":"10.1089\/cap.1990.1.87"},{"key":"2021120902192030400_R20","doi-asserted-by":"crossref","unstructured":"Arnsten AF, Cai JX, Goldman-Rakic PS. The alpha-2 adrenergic agonist guanfacine improves memory in aged monkeys without sedative or hypotensive side effects: evidence for alpha-2 receptor subtypes. J Neurosci.\u20081988;8:4287\u20134298","DOI":"10.1523\/JNEUROSCI.08-11-04287.1988"},{"key":"2021120902192030400_R21","doi-asserted-by":"crossref","unstructured":"Uhlen S, Wikberg JE. Delineation of rat kidney alpha 2A- and alpha 2B-adrenoceptors with [3H]RX821002 radioligand binding: computer modelling reveals that guanfacine is an alpha 2A-selective compound. Eur J Pharmacol.\u20081991;202:235\u2013243","DOI":"10.1016\/0014-2999(91)90299-6"},{"key":"2021120902192030400_R22","doi-asserted-by":"crossref","unstructured":"Newcorn JH, Schulz K, Harrison M, DeBellis MD, Udarbe JK, Halperin JM. Alpha 2 adrenergic agonists: neurochemistry, efficacy, and clinical guidelines for use in children. Pediatr Clin North Am.\u20081998;45:1099\u20131022, viii","DOI":"10.1016\/S0031-3955(05)70064-X"},{"key":"2021120902192030400_R23","doi-asserted-by":"crossref","unstructured":"Sorkin EM, Heel RC. Guanfacine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the treatment of hypertension. Drugs.\u20081986;31:301\u2013336","DOI":"10.2165\/00003495-198631040-00003"},{"key":"2021120902192030400_R24","doi-asserted-by":"crossref","unstructured":"Horrigan JP, Barnhill LJ. Guanfacine for treatment of attention-deficit hyperactivity disorder in boys. J Child Adolesc Psychopharmacol.\u20081995;5:215\u2013223","DOI":"10.1089\/cap.1995.5.215"},{"key":"2021120902192030400_R25","doi-asserted-by":"crossref","unstructured":"Kugler J, Seus R, Krauskopf R, Brecht HM, Raschig A. Differences in psychic performance with guanfacine and clonidine in normotensive subjects. Br J Clin Pharmacol.\u20081980;10(suppl 1):71S\u201380S","DOI":"10.1111\/j.1365-2125.1980.tb04909.x"},{"key":"2021120902192030400_R26","doi-asserted-by":"crossref","unstructured":"Balldin J, Berggren U, Eriksson E, Lindstedt G, Sundkler A. Guanfacine as an alpha-2-agonist inducer of growth hormone secretion: a comparison with clonidine. Psychoneuroendocrinology.\u20081993;18:45\u201355","DOI":"10.1016\/0306-4530(93)90054-O"},{"key":"2021120902192030400_R27","doi-asserted-by":"crossref","unstructured":"Chappell PB, Riddle MA, Scahill L, et al. Guanfacine treatment of comorbid attention-deficit hyperactivity disorder and Tourette's syndrome: preliminary clinical experience. J Am Acad Child Adolesc Psychiatry.\u20081995;34:1140\u20131146","DOI":"10.1097\/00004583-199509000-00010"},{"key":"2021120902192030400_R28","doi-asserted-by":"crossref","unstructured":"Scahill L, Chappell PB, Kim YS, et al. A placebo-controlled study of guanfacine in the treatment of children with tic disorders and attention deficit hyperactivity disorder. Am J Psychiatry.\u20082001;158:1067\u20131074","DOI":"10.1176\/appi.ajp.158.7.1067"},{"key":"2021120902192030400_R29","doi-asserted-by":"crossref","unstructured":"Taylor FB, Russo J. Comparing guanfacine and dextroamphetamine for the treatment of adult attention-deficit\/hyperactivity disorder. J Clin Psychopharmacol.\u20082001;21:223\u2013228","DOI":"10.1097\/00004714-200104000-00015"},{"key":"2021120902192030400_R30","unstructured":"Center for Drug Evaluation and Research. Guidance for Industry: E14 Clinical Evaluation of QT\/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs. Rockville, MD: Food and Drug Administration, US Department of Health and Human Services; 2005. Available at: www.fda.gov\/cder\/guidance\/6922fnl.htm. Accessed December 7, 2006"},{"key":"2021120902192030400_R31","doi-asserted-by":"crossref","unstructured":"Kelsey DK, Sumner CR, Casat CD, et al. Once-daily atomoxetine treatment for children with attention-deficit\/hyperactivity disorder, including an assessment of evening and morning behavior: a double-blind, placebo-controlled trial. Pediatrics.\u20082004;114(1). Available at: www.pediatrics.org\/cgi\/content\/full\/114\/1\/e1","DOI":"10.1542\/peds.114.1.e1"},{"key":"2021120902192030400_R32","doi-asserted-by":"crossref","unstructured":"Michelson D, Faries D, Wernicke J, et al. Atomoxetine in the treatment of children and adolescents with attention-deficit\/hyperactivity disorder: a randomized, placebo-controlled, dose-response study. Pediatrics.\u20082001;108(5). Available at: www.pediatrics.org\/cgi\/content\/full\/108\/5\/e83","DOI":"10.1542\/peds.108.5.e83"},{"key":"2021120902192030400_R33","doi-asserted-by":"crossref","unstructured":"Michelson D, Allen AJ, Busner J, et al. Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: a randomized, placebo-controlled study. Am J Psychiatry.\u20082002;159:1896\u20131901","DOI":"10.1176\/appi.ajp.159.11.1896"},{"key":"2021120902192030400_R34","doi-asserted-by":"crossref","unstructured":"Spencer T, Heiligenstein JH, Biederman J, et al. Results from 2 proof-of-concept, placebo-controlled studies of atomoxetine in children with attention-deficit\/hyperactivity disorder. J Clin Psychiatry.\u20082002;63:1140\u20131147","DOI":"10.4088\/JCP.v63n1209"},{"key":"2021120902192030400_R35","doi-asserted-by":"crossref","unstructured":"Biederman J, Swanson JM, Wigal SB, et al. Efficacy and safety of modafinil film\u2013coated tablets in children and adolescents with attention-deficit\/hyperactivity disorder: results of a randomized, double-blind, placebo-controlled, flexible-dose study. Pediatrics.\u20082005;116(6). Available at: www.pediatrics.org\/cgi\/content\/full\/116\/6\/e777","DOI":"10.1542\/peds.2005-0617"},{"key":"2021120902192030400_R36","doi-asserted-by":"crossref","unstructured":"Spencer T, Biederman J, Heiligenstein J, et al. An open-label, dose-ranging study of atomoxetine in children with attention deficit hyperactivity disorder. J Child Adolesc Psychopharmacol.\u20082001;11(3);251\u2013265","DOI":"10.1089\/10445460152595577"}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/121\/1\/e73\/1122098\/zpe00108000e73.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/121\/1\/e73\/1122098\/zpe00108000e73.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,15]],"date-time":"2023-05-15T10:40:31Z","timestamp":1684147231000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/121\/1\/e73\/71017\/A-Randomized-Double-Blind-Placebo-Controlled-Study"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,1,1]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2008,1,1]]},"published-print":{"date-parts":[[2008,1,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.2006-3695","relation":{},"ISSN":["0031-4005","1098-4275"],"issn-type":[{"value":"0031-4005","type":"print"},{"value":"1098-4275","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,1,1]]}}}